Economic burden of select adverse events (AEs) in patients (Pts) with advanced urothelial cancer (aUC) treated with first-line (1L) systemic therapy.

被引：1
|
作者：
Grivas, Petros
Laliberte, Francois
Doleh, Yunes
O'Connor, Cristi
Duh, Mei Sheng
Shenolikar, Rahul
机构：
[1] Univ Washington, Seattle Canc Care Alliance, Seattle, WA 98195 USA
[2] Grp Anal Ltee, Montreal, PQ, Canada
[3] AstraZeneca, Gaithersburg, MD USA
[4] Anal Grp Inc, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期
关键词：
D O I：
10.1200/JCO.2019.37.7_suppl.363
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
363
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS)
    Kudo, Masatoshi
    Finn, Richard S.
    Meyer, Tim
    Boisserie, Frederic
    Li, Songzi
    Chen, Yaxi
    Abdrashitov, Ramil
    Zhu, Andrew X.
    Vogel, Arndt
    Qin, Shukui
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [42] First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohort
    Cheng, Y.
    Yu, Y.
    Fan, Y.
    Jiang, L.
    Wu, L.
    Hu, J.
    Wang, J.
    Yao, W.
    Han, Z.
    Yao, Y.
    Fang, J.
    Sun, M.
    Wang, Q.
    Pan, Y.
    Wu, R.
    Liu, J.
    Liu, Y.
    Kulkarni, D.
    Huang, X.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2023, 34 : S1689 - S1689
  • [43] HEALTHCARE RESOURCE UTILIZATION (HCRU) AND COST STUDIES IN PATIENTS RECEIVING FIRST-LINE (1L) THERAPY FOR ADVANCED OR METASTATIC UROTHELIAL CARCINOMA (MUC): A SYSTEMATIC LITERATURE REVIEW (SLR)
    Auti, P.
    Braun, N.
    Arca, E.
    Teitsson, S.
    Broughton, E.
    May, J. R.
    Kurt, M.
    Alleman, C.
    VALUE IN HEALTH, 2022, 25 (01) : S70 - S70
  • [44] Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Results from patients with ≥12 mo of treatment in JAVELIN Bladder 100
    Aragon-Ching, J. B.
    Grivas, P.
    Loriot, Y.
    Bellmunt, J.
    Wang, J.
    Michelon, E.
    di Pietro, A.
    Powles, T. B.
    Sridhar, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1343 - S1343
  • [45] Tumour genomics in patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with first-line (1L) osimertinib in the phase II ELIOS study
    Ahn, M-J.
    Cho, B. C.
    Pang, Y. K.
    Voon, P. J.
    Kim, S-W.
    De Castro Carpeno, J.
    Tiseo, M.
    Li, J.
    Servidio, L.
    Sadow, S.
    Markovets, A.
    Tang, K. H.
    Piotrowska, Z.
    ANNALS OF ONCOLOGY, 2022, 33 : S1563 - S1564
  • [46] First-line nivolumab plus ipilimumab in advanced melanoma patients previously treated with adjuvant systemic therapy
    Kozak, K.
    Teterycz, P.
    Galus, L.
    Mackiewicz, J.
    Brandys, P.
    Cybulska-Stopa, B.
    Kempa-Kaminska, N.
    Zietek, M.
    Zubrowska, J.
    Dziura, R.
    Sobczuk, P.
    Czarnecka, A. M.
    Rutkowski, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S666 - S666
  • [47] Site-Specific Response Patterns in Patients with Advanced NSCLC Treated with First-Line Systemic Therapy
    Brown, L. J.
    Ahn, J.
    Gao, B.
    Gee, H.
    Nagrial, A.
    Hau, E.
    da Silva, I. Pires
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S625 - S625
  • [48] First-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) in Asian patients (pts) with advanced non-small cell lung cancer (aNSCLC) in CheckMate 227
    O'Byrne, K. J.
    Lee, K. H.
    Kim, S-W.
    Park, K.
    Nishio, M.
    Sakai, H.
    Ohe, Y.
    Fukuhara, T.
    Kang, J-H.
    Daga, H.
    Yu, C-J.
    Hotta, K.
    Tanaka, H.
    Takeda, M.
    Yokoyama, T.
    Nathan, F. E.
    Lee, J-S.
    ANNALS OF ONCOLOGY, 2020, 31 : S824 - S824
  • [49] Pemetrexed (PEM) maintenance versus observation (OBS) in patients (pts) with advanced urothelial carcinoma (aUC) who completed first-line (1L) platinum-based chemotherapy (CTx) without disease progression (PREMIER, KCSG GU16-05).
    Park, Inkeun
    Yoon, Shinkyo
    Kim, Il Hwan
    Park, Kwonoh
    Lee, Suee
    Keam, Bhumsuk
    Park, Joo-Hwan
    Kim, Jin Young
    Choi, Yoon Ji
    Sohn, Byeong Seok
    Lee, Jae-Lyun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 621 - 621
  • [50] First-line checkpoint inhibitors in PD-L1-positive patients with advanced urothelial carcinoma
    Tsimafeyeu, Ilya
    Tjulandin, Sergei
    BJU INTERNATIONAL, 2019, 123 (04) : 563 - 565
12345